Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer. [electronic resource]
Producer: 20160819Description: 894 p. digitalISSN:- 1471-2407
- Animals
- Antineoplastic Agents -- pharmacology
- Apoptosis -- drug effects
- Cell Cycle -- drug effects
- Cell Line, Tumor
- Cell Proliferation -- drug effects
- Cell Survival -- drug effects
- Disease Models, Animal
- Dose-Response Relationship, Drug
- Drug Resistance, Neoplasm
- G1 Phase Cell Cycle Checkpoints -- drug effects
- Humans
- Imidazoles -- pharmacology
- Mice
- Phosphoinositide-3 Kinase Inhibitors
- Quinolines -- pharmacology
- Receptor, ErbB-2 -- metabolism
- Signal Transduction -- drug effects
- Stomach Neoplasms -- drug therapy
- TOR Serine-Threonine Kinases -- antagonists & inhibitors
- Trastuzumab -- pharmacology
- Tumor Burden -- drug effects
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.